Publication:
Role of serum hyaluronic acid in predicting necroinflammatory activity of the nonalcoholic fatty liver disease

dc.contributor.authorhakan güveli
dc.contributor.authorOya Ovunc Kurdas
dc.contributor.institutionBAHÇEŞEHİR ÜNİVERSİTESİ
dc.contributor.institutionT.C. SAĞLIK BAKANLIĞI
dc.date.accessioned2025-09-20T19:56:22Z
dc.date.issued2022
dc.date.submitted18.05.2023
dc.description.abstractBackground and Aim: Hyaluronic acid (HA), a fundamental component of the extracellular matrix, is associated with chronic liver diseases. The aim of this study was to investigate quantitative HA measurement as a non- invasive marker for steatosis and fibrosis staging in nonalcoholic fatty liver disease (NAFLD) with biopsy evidence. Materials and Methods: In this study, 52 NAFLD patients with biopsy evidence and who met the inclusion criteria were included. Hepatic enzyme levels, HA levels, and other laboratory findings were examined. In addition, the degree of steatosis was determined via computed tomography (CT). Results: According to the degree of steatosis, HA levels were 29.17±22.66, 39.85±60.28, and 32.05±19.40, respectively, and no significant difference was found between the groups (p=0.584). In addition, HA levels were not found to be significant according to the degrees of steatohepatitis (p=0.860). However, a statistically significant relationship was found between steatosis levels detected by CT and biopsy (p<0.01). Conclusion: Serum HA level, other biochemical parameters, and steatosis severity measurement via CT did not appear to have any diagnostic value for nonalcoholic steatohepatitis. In this context, novel markers that may be useful for NAFLD diagnosis and severity assessment in risky individuals should be investigated.
dc.identifier.doi10.14744/hf.2022.2022.0004
dc.identifier.endpage50
dc.identifier.issn1307-5888
dc.identifier.issn1307-5888
dc.identifier.issue2
dc.identifier.startpage45
dc.identifier.urihttps://hdl.handle.net/20.500.14719/4675
dc.identifier.volume3
dc.language.isoen
dc.relation.journalHepatology forum
dc.subjectGenel ve Dahili Tıp
dc.subjectPatoloji
dc.subjectTemel Sağlık Hizmetleri
dc.subjectSağlık Bilimleri ve Hizmetleri
dc.titleRole of serum hyaluronic acid in predicting necroinflammatory activity of the nonalcoholic fatty liver disease
dc.typeResearch Article
dcterms.references1. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006,6(1):33.,2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018,67(1):328-357.,3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Glob- al epidemiology of nonalcoholic fatty liver disease—meta-analytic assess- ment of prevalence, incidence, and outcomes. Hepatology 2016,64(1):73- 84.,4. Poynard T, Munteanud M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, et al. Impact of steatosis and inflammation definitions on the performance of NASH tests. European Journal of Gastroenterol Hepatol 2018,30(4):384- 391.,5. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in mor- bidly obese patients. Obes Surg 2005,15(3):310-315.,6. Serfatya L, Lemoinea M. Definition and natural history of metabolic ste- atosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008,34(6 Pt 2):634-637.,7. Alizadeh A, Mansour-Ghanaei F, Roozdar A, Joukar F, Sepehrimanesh M, Hojati SA, et al. Laboratory tests, liver vessels color doppler sonography, and fibroscan findings in patients with nonalcoholic fatty liver disease: An observation study. J Clin Imaging Sci 2018,8:12.,8. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Ari- da A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010,52(3):913- 924.,9. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology 2017,66(5):1486-1501.,10. Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016,89(1):24-31.,11. Rockey DC, Montgomery B. Noninvasive measures of liver fibrosis. Hepa- tology. 2006,43(2 Suppl 1):S113-S120.,12. Ponomarenko Y, Leo MA, Kroll W, Lieber CS. Effects of alcohol con- sumption on eight circulating markers of liver fibrosis. Alcohol Alcohol 2002,37(3):252-255.,13. Irak K, Eminler AT, Ayyildiz T, Keskin M, Nak SG, Kiyici M, et al. The relationship of the degree of hepatic fibrosis with hyaluronic acid, type 4 collagen, and procollagentype 3 n-terminal peptide levels in patients with chronic viral hepatitis. Viral Hepat J 2015,21(1):8-12.,14. McHutchison JG, Blatt LM, Medina MD, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000,15(8):945-951.,15. Cen C, Wang W, Yu S, Tang, X, Liu J, Liu Y, et al. Development and vali- dation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease. Hepatol Int 2020,14(5):808-816.,16. Fujita N, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Takayama Y, et al. Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry. World J Gastroenterol 2016,22(40):8949- 8955.,17. Baranova A, Younossi ZM. The future is around the corner: noninva- sive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 2008,47(2):373-375.,18. Zheng M, Chengliang C, Chen Y, Gopal N, Ramesh R, Jiao J. Diagnostic performance of fibroscan and computed tomography in 322 normal alanine aminotransferase non- obese non-alcoholic fatty liver disease patients diag- nosed by ultrasound. Int J Clin Pract 2020,74(12):e13635.,19. Baek J, Jung SJ, Shim JS, Jeon YW, Seo E, Kim HC. Comparison of Com- puted Tomography-based Abdominal Adiposity Indexes as Predictors of Non-alcoholic Fatty Liver Disease Among Middle-aged Korean Men and Women. J Prev Med Public Health 2020,53(4):256-265.,20. Rabbitt LA, McNally M, Reynolds L, Hinchion K, Simpkin A, Scarry M, et al. A prospective cohort study of the use of the fatty liver index and Fibros- can to determine the prevalence of fatty liver disease in an Irish population. Eur J Gastroenterol Hepatol 2022,34(2):200-205.,21. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepa- tol 2009,51(2):371-379.,22. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014,20(23):7392-7402.,23. Wang N, Dong H, Wei S, Lu F. Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease. J Huazhong Univ Sci Technolog Med Sci 2008,28(3):295-298.,24. Han MAT. Noninvasive tests (NITs) for hepatic fibrosis in fatty liver syn- drome. Life (Basel) 2020,10(9):198.,25. Ueno T, Inuzuka S, Torimura T, Tamaki S, Koh H, Kin M, et al. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology 1993,105(2):475-481.,26. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, et al. Noninvasive serum markers in the diagnosis of structural liver dam- age in chronic hepatitis C virus infection. Liver Int 2006,26(9):1095-1099.,27. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-as- sociated liver disease. World J Gastroenterol 2005,11(4):476-481.,28. Zeng M, Lu L, Mao Y, Qiu D, Li J, Wan M, et al. Prediction of significant fi- brosis in HBeAg-positivepatients with chronic hepatitis B by a noninvasive model. Hepatology 2005,42(6):1437-1445.
dspace.entity.typePublication
local.indexed.atTRDizin

Files